The Future of Targeted Therapeutics

In recent years, the maximization of blockbuster revenues has been compromised by generic price erosion and a decline in new drug approvals. Large pharmaceutical companies are coming under pressure to explore new R&D strategies and implement more cost-effective sourcing methods for innovative new molecules.

The biotechnology industry is emerging as a hub of innovation for biomarker and new chemical entity (NCE) identification, and has become a vital component in the preclinical development of new drug technologies. As therapeutic focus shifts to treating the causal pathway of disease and not merely symptomology, the majority of emerging targeted therapeutics are large molecule biologics while monoclonal antibody therapies represents one of the fastest-growing segment within the pharmaceutical industry.

The Future of Targeted Therapeutics: Key technologies, new therapy area applications and leading players is a new report published by Business Insights that examines various types of targeted therapies within Pharma pipelines, highlighting the molecules of greatest significance to major therapy areas. The key revenue drivers and product focus within targeted technology markets are also assessed.

This report also measures the impact of the new model of targeted therapeutic development upon stakeholder demand and health economics.
Discover the most promising targeted molecules within each therapeutic area, identify the pipeline potential of leading companies and align your R&D strategies with the latest innovations and development models.

Top five reasons to order your copy today
• Understand stakeholder incentives in the future of targeted therapeutics, including public and private payors, regulatory bodies, physicians, patients and healthcare providers.
• Discover the strategic initiatives used by various biopharmaceutical companies in the development of targeted therapies within the areas of Oncology, CNS, Cardiovascular and Anti-Infectives.
• Assess the current stages of development and clinical potential of key molecular targeted drugs by technology type and therapy area.
• Identify and view key examples of the different types of molecules that are strengthening pipelines for targeted therapeutics and understand their mechanisms of action.
• Assess unmet needs within different therapy areas that are promoting the development of new targeted therapies and anticipate how such therapies will compete with currently marketed treatments.

Key issues examined in this report...
• Declining blockbuster revenues. Blockbuster-generated revenues grew by a mere 5.1% over 2005-06, well below the 7.0% total growth registered by the global pharma market. This trend has been heavily influenced by patent expiration and generic entry, which typically result in blockbuster prices falling to 70-90% of their original value.
• Patient populations and drug focus. Patient compliance issues and the variable efficacy and bioavailability of therapies in different patient populations is driving segmentation within therapy markets.
• Clinical trial failures. NCE approval rates have experienced an overall decline which has been compounded by drug application failures across all industry sectors; for every FDA drug approval during 2005-07, 1.6 phase III failures were recorded.
• Reimbursement and health economics. At present rates of development, costs per treatment for innovative small molecule drugs and biologics will exceed those witnessed during the blockbuster era.

Your questions answered...
• Which treatment areas offer the greatest patient potential and future value for targeted therapies?
• What are the key targeted therapies currently in development for major disease areas related to cancer, cardiovascular and CNS?
• How have markets been affected by targeted therapy launches?
• To what extent will existing treatment models and plans need modification?
• What are the implications for health economics?
• Which biotechnology companies are creating advanced proprietary technologies to develop targeted therapies?
• How can the barriers to successful targeted therapy launches be overcome to maximize revenues?